Quoin Pharmaceuticals
QNRX
3 hedge funds and large institutions have $52K invested in Quoin Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 4 closing their positions.
0% less ownership
Funds ownership: 0% → 0% (-0%)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
50% less funds holding
Funds holding: 6 → 3 (-3)
75% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 4
81% less capital invested
Capital invested by funds: $272K → $52K (-$220K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$11.3K |
| 2 |
ASN
Advisory Services Network
Atlanta,
Georgia
|
+$7.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GSC
Ground Swell Capital
Folly Beach,
South Carolina
|
-$82K |
| 2 |
VF
Virtu Financial
New York
|
-$67K |
| 3 |
Jane Street
New York
|
-$26K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$24K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$12.8K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $31.1K | +$11.3K | +15 | +41% |
|
|
2
Citadel Advisors
Miami,
Florida
| $15.1K | -$12.8K | -17 | -40% |
|
|
ASN
3
Advisory Services Network
Atlanta,
Georgia
| $5.68K | +$7.5K | +10 | New |
|
4
Morgan Stanley
New York
| $111 | – | – | – |
|
|
HNB
5
Huntington National Bank
Columbus,
Ohio
| $6 | – | – | – |
|
|
GSC
6
Ground Swell Capital
Folly Beach,
South Carolina
| – | -$82K | -87 | Closed |
|
|
VF
7
Virtu Financial
New York
| – | -$67K | -71 | Closed |
|
|
8
Jane Street
New York
| – | -$26K | -28 | Closed |
|
|
9
UBS Group
Zurich,
Switzerland
| – | -$24K | -25 | Closed |
|
QNRX Hedge Fund Activity: Q4 2022 in Review
3 of the 6,223 institutional investors tracked by Wall St. Rank reported a position in Quoin Pharmaceuticals (QNRX) for Q4 2022, worth a combined $52K — down 81% from $272K a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of QNRX and 1 opened new positions — a net loss of 3 holders — while 1 trimmed existing stakes and 1 added.
The largest buyer was Susquehanna International Group, adding an estimated $11.3K. The largest seller was Ground Swell Capital, exiting entirely with an estimated $82K sold.
- 3 institutional investors held Quoin Pharmaceuticals (QNRX) as of Q4 2022, down from 6 in Q3 2022.
- Funds reported $52K of Quoin Pharmaceuticals stock for Q4 2022, down 81% quarter-over-quarter.
- 1 fund opened new Quoin Pharmaceuticals positions in Q4 2022 and 4 closed out, a net change of -3 holders.
- The largest Quoin Pharmaceuticals buyer in Q4 2022 was Susquehanna International Group, an estimated $11.3K added.
- The largest Quoin Pharmaceuticals seller in Q4 2022 was Ground Swell Capital, an estimated $82K sold.
Based on aggregated 13F filings for Q4 2022.